Cargando…

Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease—Current Background, Hopes, and Perspectives

Nonalcoholic fatty liver disease (NAFLD) represents the most common chronic liver disease worldwide, reaching one of the highest prevalences in patients with type 2 diabetes mellitus (T2DM). For now, no specific pharmacologic therapies are approved to prevent or treat NAFLD. Glucagon-like peptide-1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cazac, Georgiana-Diana, Lăcătușu, Cristina-Mihaela, Ștefănescu, Gabriela, Mihai, Cătălina, Grigorescu, Elena-Daniela, Onofriescu, Alina, Mihai, Bogdan-Mircea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221116/ https://www.ncbi.nlm.nih.gov/pubmed/37233622 http://dx.doi.org/10.3390/metabo13050581

Ejemplares similares

New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis
por: Cazac, Georgiana-Diana, et al.
Publicado: (2022)

Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes
por: Cazac, Georgiana-Diana, et al.
Publicado: (2022)

Effects of Incretin-Based Treatment on the Diastolic (Dys)Function in Patients with Uncontrolled Type 2 Diabetes Mellitus: A Prospective Study with 1-Year Follow-Up
por: Grigorescu, Elena-Daniela, et al.
Publicado: (2023)

Association of Inflammatory and Metabolic Biomarkers with Mitral Annular Calcification in Type 2 Diabetes Patients
por: Grigorescu, Elena-Daniela, et al.
Publicado: (2022)

The Mediterranean Diet: From an Environment-Driven Food Culture to an Emerging Medical Prescription
por: Lăcătușu, Cristina-Mihaela, et al.
Publicado: (2019)

Association of Antihyperglycemic Therapy with Risk of Atrial Fibrillation and Stroke in Diabetic Patients
por: Lăcătușu, Cristina-Mihaela, et al.
Publicado: (2019)

Self-Reported Satisfaction to Treatment, Quality of Life and General Health of Type 2 Diabetes Patients with Inadequate Glycemic Control from North-Eastern Romania
por: Grigorescu, Elena-Daniela, et al.
Publicado: (2021)

Bidirectional Relationship between Gastric Emptying and Plasma Glucose Control in Normoglycemic Individuals and Diabetic Patients
por: Mihai, Bogdan Mircea, et al.
Publicado: (2018)

Left Ventricular Diastolic Dysfunction in Type 2 Diabetes—Progress and Perspectives
por: Grigorescu, Elena-Daniela, et al.
Publicado: (2019)

Insulin resistance and adipokine levels correlate with early atherosclerosis – a study in prediabetic patients
por: Mihai, Bogdan Mircea, et al.
Publicado: (2014)

Ischemic Heart Disease in Patients with Inflammatory Bowel Disease: Risk Factors, Mechanisms and Prevention
por: Jucan, Alina Ecaterina, et al.
Publicado: (2022)

The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus
por: Salmen, Teodor, et al.
Publicado: (2023)

Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease
por: Lee, Han Ah, et al.
Publicado: (2023)

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
por: Mantovani, Alessandro, et al.
Publicado: (2021)

The Intertwining Roads between Psychological Distress and Gut Microbiota in Inflammatory Bowel Disease
por: Gîlcă-Blanariu, Georgiana-Emmanuela, et al.
Publicado: (2023)

The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD)
por: Tanase, Daniela Maria, et al.
Publicado: (2020)

Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis
por: Kojima, Motoyasu, et al.
Publicado: (2020)

Thiazolidinediones and Glucagon‐Like Peptide‐1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study
por: van Dalem, Judith, et al.
Publicado: (2021)

Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease
por: Gîlcă-Blanariu, Georgiana-Emmanuela, et al.
Publicado: (2023)

Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus
por: Onoviran, Olusola F., et al.
Publicado: (2019)

Evaluation of Disease Activity in Inflammatory Bowel Disease: Diagnostic Tools in the Assessment of Histological Healing
por: Jucan, Alina Ecaterina, et al.
Publicado: (2023)

Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis
por: Park, Min Jeong, et al.
Publicado: (2023)

The molecular pharmacology of glucagon agonists in diabetes and obesity
por: Novikoff, Aaron, et al.
Publicado: (2023)

Design of Glucagon-Like Peptide-1 Receptor Agonist for Diabetes Mellitus from Traditional Chinese Medicine
por: Tang, Hsin-Chieh, et al.
Publicado: (2014)

Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
por: Cho, Young Min, et al.
Publicado: (2013)

Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response
por: Crisan, Dana, et al.
Publicado: (2017)

Terahertz Spectroscopy and Imaging: A Cutting-Edge Method for Diagnosing Digestive Cancers
por: Danciu, Mihai, et al.
Publicado: (2019)

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review
por: Lv, Xiaodan, et al.
Publicado: (2020)

Effect of glucagon-like peptide-1 receptor agonists on adipokine level of nonalcoholic fatty liver disease in rats fed high-fat diet
por: Jin, Miaomiao, et al.
Publicado: (2020)

Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus
por: Pelle, Maria Chiara, et al.
Publicado: (2023)

Navigating through the Lipid Metabolism Maze: Diagnosis and Prognosis Metabolites of Hepatocellular Carcinoma versus Compensated Cirrhosis
por: Nenu, Iuliana, et al.
Publicado: (2022)

Lung Ultrasound-Guided Fluid Management versus Standard Care in Surgical ICU Patients: A Randomised Controlled Trial
por: Rusu, Daniel-Mihai, et al.
Publicado: (2021)

Safety Indices during Fetal Echocardiography at the Time of First-Trimester Scan Are Machine Dependent
por: Nemescu, Dragos, et al.
Publicado: (2015)

High hopes for cannabinoid agonists in the treatment of rheumatic diseases
por: Staunton, Caroline A, et al.
Publicado: (2014)

Severe Acute Pancreatitis Treated with Negative Pressure Wound Therapy System: Influence of Laboratory Markers
por: Ciuntu, Bogdan Mihnea, et al.
Publicado: (2023)

Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro)
por: Bala, Cornelia, et al.
Publicado: (2022)

The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus
por: Brice, Kira R., et al.
Publicado: (2011)

A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
por: Kalra, Sanjay, et al.
Publicado: (2020)

New onset severe ulcerative colitis following Ixekizumab therapy
por: Morosanu, Alina Mihaela, et al.
Publicado: (2022)

Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis
por: Yuan, Xia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n974e5i3k339esfssocvlujk0e